Healio

Subcutaneous immunotherapy not linked to severe reactions in severe asthma

Please provide your email address to receive an email when new articles are posted on . The total patient population experienced a rate of 19.9 severe reactions per 10,000 injection visits. Patients ...
The American Journal of Managed Care

Subcutaneous Ocrelizumab Well Tolerated in Patients With MS

Subcutaneous ocrelizumab (SC OCR) maintains a safety profile similar to intravenous administration in multiple sclerosis patients. A 920 mg SC OCR dose was identified as optimal, with mild to moderate ...
The American Journal of Managed Care

Subcutaneous Treatments Can Save Chair Time, Decrease Infusion Reaction in NSCLC: Joshua K. Sabari, MD

Subcutaneous therapy could be the future of non–small cell lung cancer (NSCLC) as it would decrease time needed for treatment. Joshua K. Sabari, MD, director of High Reliability Organization ...
Medscape

Subcutaneous Ocrelizumab, Ofatumumab 'Reassuring' in MS

MILAN — Subcutaneous administration of anti-CD20 monoclonal antibody therapy offers ongoing clinical efficacy in the management of patients with relapsing and primary progressive multiple sclerosis ...
Medscape

What Should I Know About Enfuvirtide (T-20) Injection-Site Reactions?

Of particular concern are patients with severe lipoatrophy of the extremities. These individuals or their caregivers may need to search for sites with more subcutaneous fat to avoid injection into the ...
Business Wire

Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions

– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...
MedPage Today

Subcutaneous Ocrelizumab Not Inferior to IV Infusion

MILAN -- An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase III ...
SurvivorNet on MSN

Targeted therapy in a shot: New approval for EGFR-mutated lung cancer can improve day-to-day life for patients

Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...
Business Wire

Positive Phase III Results for Genentech’s Ocrevus (ocrelizumab) Twice a Year, 10-Minute Subcutaneous Injection in Patients With Multiple Sclerosis

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase III OCARINA II trial evaluating Ocrevus® (ocrelizumab) ...
Targeted Oncology

FDA Approves Subcutaneous Mosunetuzumab in Follicular Lymphoma

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous (SC) formulation for the treatment of adult ...
Nasdaq

FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis

Basel, 16 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the United States Food and Drug Administration (U.S. FDA) has approved OCREVUS ZUNOVO™ (ocrelizumab & hyaluronidase-ocsq) ...